Read by QxMD icon Read

Hematological Oncology

Yi-Lun Chen, Yao-Chung Liu, Chia-Hung Wu, Chiu-Mei Yeh, Hsun-I Chiu, Gin-Yi Lee, Yu-Ting Lee, Pei Hsu, Ting-Wei Lin, Jyh-Pyng Gau, Liang-Tsai Hsiao, Tzeon-Jye Chiou, Jin-Hwang Liu, Chia-Jen Liu
Vertebral fractures affect approximately 30% of myeloma patients and lead to a poor impact on survival and life quality. In general, age and body mass index (BMI) are reported to have an important role in vertebral fractures. However, the triangle relationship among age, BMI, and vertebral fractures is still unclear in newly diagnosed multiple myeloma (NDMM) patients. This study recruited consecutive 394 patients with NDMM at Taipei Veterans General Hospital between January 1, 2005 and December 31, 2015. Risk factors for vertebral fractures in NDMM patients were collected and analyzed...
November 6, 2017: Hematological Oncology
Pavel Klener, Eva Fronkova, David Belada, Kristina Forsterova, Robert Pytlik, Marketa Kalinova, Martin Simkovic, David Salek, Heidi Mocikova, Vit Prochazka, Petra Blahovcova, Andrea Janikova, Jana Markova, Ales Obr, Adela Berkova, Jozef Kubinyi, Martina Vaskova, Ester Mejstrikova, Vit Campr, Radek Jaksa, Roman Kodet, Kyra Michalova, Jan Trka, Marek Trneny
Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational study that prospectively analyzed safety and efficacy of alternating 3 + 3 cycles of R-CHOP and R-cytarabine for newly diagnosed transplant-ineligible MCL patients. A total of 73 patients were enrolled with median age 70 years...
October 30, 2017: Hematological Oncology
Marcel Nijland, Karin Boslooper, Gustaaf van Imhoff, Robbie Kibbelaar, Peter Joosten, Huib Storm, Eric N van Roon, Arjan Diepstra, Hanneke C Kluin-Nelemans, Mels Hoogendoorn
Despite a general favourable outcome in limited stage diffuse large B-cell lymphoma (DLBCL), relapses occur in about 10 to 20% of patients. Prognostic models only partially identify patients at risk for relapse. Moreover, it is not known whether the outcome after such a relapse is similar to the outcome after relapse in advanced stages. From January 2004 through December 2012, all newly diagnosed patients with stage I(E) DLBCL were retrospectively analysed from 2 clinical databases to investigate the relapse pattern and outcome in relation to initial treatment and clinical characteristics...
October 30, 2017: Hematological Oncology
Fabio Guolo, Mariella Ferrari, Paola Minetto, Cristina Matteo, Marino Clavio, Elisa Coviello, Filippo Ballerini, Maurizio Miglino, Marco Gobbi, Maurizio D'Incalci, Roberto Massimo Lemoli, Massimo Zucchetti
No abstract text is available yet for this article.
October 20, 2017: Hematological Oncology
Keisuke Kawamoto, Hiroaki Miyoshi, Takaharu Suzuki, Yuya Sasaki, Kyohei Yamada, Eriko Yanagida, Reiji Muto, Maiko Kiryu, Hirohito Sone, Masao Seto, Koichi Ohshima, Jun Takizawa
Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is a subtype of non-Hodgkin lymphoma with a poor prognosis. Although first-line treatments for patients with localized ENKTL have been established, there is no gold standard treatment for patients with advanced ENKTL and refractory and/or relapsed disease. Anti-CD30 antibody-based therapy, including brentuximab vedotin (BV), has been shown to target malignant lymphomas with CD30 expression. In particular, this therapeutic agent has recently been suggested to be effective for Hodgkin lymphoma and mature T-cell lymphoma...
October 20, 2017: Hematological Oncology
Florence Ranchon, Nicolas Vantard, Emilie Henin, Emmanuel Bachy, Clémentine Sarkozy, Lionel Karlin, Fadhela Bouafia-Sauvy, Aurore Gouraud, Verane Schwiertz, Estelle Bourbon, Amandine Baudouin, Anne Gaelle Caffin, Thierry Vial, Gilles Salles, Catherine Rioufol
The aim of this retrospective cohort study was to investigate the incidence of delayed methotrexate elimination in patients treated with high-dose methotrexate (≥1 g/m(2) ) for haematological malignancy and to identify the impact of interacting drugs, especially proton-pump inhibitors (PPIs) and ranitidine. All patients treated with high-dose methotrexate over a 6 year period in the haematology department of the Lyon Sud University Hospital (Hospices Civils de Lyon, France) were included. Potential risk factors for delayed methotrexate elimination were tested in a generalized linear model by univariate analysis: patient age, gender, methotrexate dose, administration of PPI or ranitidine, and concomitant nephrotoxic drugs...
October 6, 2017: Hematological Oncology
Andrea Visentin, Chiara Briani, Silvia Imbergamo, Federica Frezzato, Annalisa Angelini, Marny Fedrigo, Mario Cacciavillani, Sara Altinier, Francesco Piazza, Gianpietro Semenzato, Fausto Adami, Livio Trentin
Light chain amyloidosis is characterized by the progressive deposition of immunoglobulin light chains into the extracellular tissue, leading to organ dysfunction. Usually, it is associated with an underlying clonal plasma cell dyscrasia and rarely with chronic lymphocytic leukaemia. Herein, we described the first report of a patient with relapsed chronic lymphocytic leukaemia harbouring TP53 abnormalities who developed, histologically proven, systemic light chain amyloidosis who was treated with the PI3K inhibitor, idelalisib, and rituximab...
October 3, 2017: Hematological Oncology
Hiroshi Ureshino, Toshihiko Ando, Haruna Kizuka, Kana Kusaba, Haruhiko Sano, Atsujiro Nishioka, Hidekazu Itamura, Takero Shindo, Yasushi Kubota, Kensuke Kojima, Shinya Kimura
It has been well documented that patients may develop cytokine-release syndrome (CRS) following the administration of monoclonal antibodies, such as chimeric antigen receptor-modified T cell. Cytokine-release syndrome is a common complication in patients who have received haploidentical donor allogeneic haematopoietic cell transplantation (haplo-HCT). Although severe CRS after haplo-HCT is a potentially life-threatening toxicity, a standard treatment has not been established. Cytokine blockade with tocilizumab, an anti-IL-6 receptor antibody, has been effective for the treatment of patients with CRS after chimeric antigen receptor-modified T-cell treatment and has also improved CRS after haplo-HCT...
October 3, 2017: Hematological Oncology
Francesco Autore, Idanna Innocenti, Marco Luigetti, Nicola Piccirillo, Federica Sora, Patrizia Chiusolo, Simona Sica, Andrea Bacigalupo, Luca Laurenti
POEMS syndrome is a rare paraneoplastic condition, with a poorly understood pathogenesis. High dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been reported to be an effective therapeutic option for patients with good performance status. Here, we review the role of ASCT for POEMS syndrome and discuss indications together with advantages and disadvantages, and related issues such lenalidomide given before or after ASCT, VEGF levels as a marker of disease, and different regimens for stem cell mobilization...
September 15, 2017: Hematological Oncology
Meixian Huang, Takeshi Inukai, Keiko Kagami, Masako Abe, Tamao Shinohara, Atsushi Watanabe, Shinpei Somazu, Hiroko Oshiro, Kumiko Goi, Hiroaki Goto, Masayoshi Minegishi, Shotaro Iwamoto, Kevin Y Urayama, Kanji Sugita
Glucocorticoid (GC) shows antileukaemic activity via binding to the GC receptor (GR). The human GR gene has 4 splicing variants besides the functional isoform GRα, but their significance in GC sensitivity of acute lymphoblastic leukaemia (ALL) has been inconsistent. Additionally, several studies evaluated the relevance of GR gene single nucleotide polymorphisms (SNPs) in the GC sensitivity of ALL, but the current cumulative evidence appears inconclusive. Addressing limitations in previous studies, we used a large series of B-cell precursor ALL (BCP-ALL) cell lines established from Japanese patients to comprehensively examine all 5 splicing variants of the GR gene and candidate SNPs, and their association with GC-sensitivity...
August 29, 2017: Hematological Oncology
Rocco Sabatino, Gabriella Aquino, Antonio Pinto, Miguel Angel Piris, Laura Marra, Maria Napolitano, Annarosaria De Chiara, Renato Franco
No abstract text is available yet for this article.
September 2017: Hematological Oncology
Nathalie Douet-Guilbert, Aurelie Chauveau, Nadia Gueganic, Gaëlle Guillerm, Corine Tous, Marie-Josee Le Bris, Audrey Basinko, Frederic Morel, Valerie Ugo, Marc De Braekeleer
Inv(16)(p13q22) and t(16;16)(p13;q22) are cytogenetic hallmarks of acute myelomonoblastic leukaemia, most of them associated with abnormal bone marrow eosinophils [acute myeloid leukaemia French-American-British classification M4 with eosinophilia (FAB AML-M4Eo)] and a relatively favourable clinical course. They generate a 5'CBFB-3'MYH11 fusion gene. However, in a few cases, although RT-PCR identified a CBFB-MYH11 transcript, normal karyotype and/or fluorescent in situ hybridization (FISH) analyses using commercially available probes are found...
September 2017: Hematological Oncology
Caroline Gay, Delphine Toulet, Pascal Le Corre
The extensive use of tyrosine kinase inhibitors (TKI's) in hematology and oncology has shown that these drugs have a significant potential for drug-drug interactions. Since these drugs have a rather low therapeutic window, some drug interactions are of particular clinical relevance either on drug toxicity or on patient's response. Significant interactions occur with concomitant use of acid-suppressive therapy leading to a decreased oral bioavailability. However, such interactions are drug dependent according to their solubility pattern and to the duration of action of acid-suppressive therapy, which is coprescribed...
September 2017: Hematological Oncology
Kosei Matsue, Yuya Matsue, Kaoru Kumata, Yoshiaki Usui, Yasuhito Suehara, Kota Fukumoto, Manabu Fujisawa, Kentaro Narita, Masami Takeuchi
Accurate quantification of plasma cells (PCs) in bone marrow (BM) is critical for diagnosis and assessment of treatment response in patients with multiple myeloma (MM). We compared the % of BM PC quantified by 250 cell differential count on May-Giemsa-stained BM smears, by counting 500 - 2500 cells in 2 - 5 representative microscopy fields in CD138-immunostained BM clot and biopsy sections, and CD38/CD45/CD138 gated BM PCs on flow cytometry (FCM) in 150 sets of BM samples from 120 patients. Percentages of PC were significantly correlated between BM biopsy and clot, and between smear and FCM (r = 0...
September 2017: Hematological Oncology
Liu Yu, Ke Chen, Ying Xu, Shubei Wang, Qianqian Liu, Qiao Ye, Tingjun Ye, Yunwei Sun
Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) have a great value in clinical practice of gastrointestinal lymphoma (GIL). Auxiliary methods such as flow cytometry (FCM) and gene rearrangement provide additional information for the diagnosis. Current study aims to explore the diagnostic value of EUS-FNA combined with FCM and gene rearrangement for GIL in our single institution. Suspected GIL cases, which were referred to EUS, FNA, FCM, or gene rearrangement examination, were retrospectively reviewed from January 2011 to May 2014...
September 2017: Hematological Oncology
Manuel Gotti, Marta Nicola, Marco Lucioni, Valeria Fiaccadori, Virginia Ferretti, Roberta Sciarra, Mariangela Costanza, Elisa Bono, Silvana Molo, Aldo Maffi, Giorgio A Croci, Marzia Varettoni, Marco Frigeni, Cristiana Pascutto, Luca Arcaini, Maurizio Bonfichi, Marco Paulli, Mario Cazzola
Although patients with early-stage Hodgkin's lymphoma have a high rate of cure, a portion of these are resistant to or relapse after standard treatment. Current prognostic criteria based on clinical and laboratory parameters at diagnosis do not allow to accurately identify the subset of patients with less favourable clinical outcome. An increased number of tumour-infiltrating macrophages was found to be associated with shortened survival in patients with classic Hodgkin's Lymphoma. The aim of this study was to assess the clinical significance of the proportion of CD68-positive infiltrating macrophages in patients with early-stage classic Hodgkin's lymphoma...
September 2017: Hematological Oncology
Yuya Sasaki, Ying Guo, Fumiko Arakawa, Hiroaki Miyoshi, Noriaki Yoshida, Yuhki Koga, Kazutaka Nakashima, Daisuke Kurita, Daisuke Niino, Masao Seto, Koichi Ohshima
Langerhans cell histiocytosis (LCH) is a rare disease characterized by clonal proliferation of CD1a- and CD207 (langerin)-positive dendritic cells. Mutated BRAF (p.V600E) is observed in histiocyte-related diseases and dendritic cell-related diseases, including LCH. BRAFV600E is observed in some LCH cases and is thought to be involved in maintaining MAPK activation. We retrospectively analyzed BRAFV600E in 19 patients diagnosed with LCH. In our study, direct sequencing for exon 15, a mutation hotspot, demonstrated that 4 out of the 19 patients (21%) harbored a GTG > GAG (valine > glutamic acid) base substitution, which encodes BRAFV600E...
September 2017: Hematological Oncology
Jing-Cheng Zhu, Meng-Ya Si, Ya-Zhen Li, Huan-Zhu Chen, Zhi-Cheng Fan, Qing-Dong Xie, Xiao-Yang Jiao
The aim of this study was to evaluate the clinical significance of circulating tight junction (TJ) proteins as biomarkers reflecting of leukaemia central nervous system (CNS) metastasis. TJs [claudin5 (CLDN5), occludin (OCLN) and ZO-1] concentrations were measured in serum and cerebrospinal fluid (CSF) samples obtained from 45 leukaemia patients. Serum ZO-1 was significantly higher (p < 0.05), but CSF ZO-1 levels were not significantly higher in the CNS leukaemia (CNSL) compared to the non-CNSL. The CNSL patients also had a lower CLDN5/ZO1 ratio in both serum and CSF than in non-CNSL patients (p < 0...
September 2017: Hematological Oncology
Takuro Matsumoto, Takeshi Hara, Yuhei Shibata, Nobuhiko Nakamura, Hiroshi Nakamura, Soranobu Ninomiya, Junichi Kitagawa, Nobuhiro Kanemura, Naoe Goto, Yusuke Kito, Senji Kasahara, Toshiki Yamada, Michio Sawada, Tatsuhiko Miyazaki, Tsuyoshi Takami, Tamotsu Takeuchi, Hisataka Moriwaki, Hisashi Tsurumi
We have reported the efficacy of the salvage chemotherapy P-IMVP16/CBDCA for patients with diffuse large B cell lymphoma (DLBCL) who had previously received CHOP before the availability of rituximab (R). Here, we confirmed the efficacy of R combined with P-IMVP16/CBDCA as a salvage chemotherapy for patients with DLBCL, who had previously received R-CHOP. We retrospectively analysed 59 patients with relapse or refractory DLBCL (38 male patients and 21 female patients) presenting between June 2004 and June 2013...
September 2017: Hematological Oncology
Shan Yuan, Joycelynne M Palmer, Ni-Chun Tsai, Andrew Dagis, Auayporn Nademanee, Shirong Wang
Plerixafor has been used to improve peripheral blood stem cell (PBSC) mobilization in multiple myeloma, non-Hodgkin lymphoma, and very recently in Hodgkin lymphoma (HL) patients. Because prior studies have suggested that mobilization with plerixafor affects the composition of mobilized cells, there are concerns that this may in turn adversely impact the immune reconstitution and longer term outcomes of transplanted patients. However, data on the engraftment characteristics and long-term post-transplant outcomes in patients transplanted with plerixafor-mobilized PBSCs are lacking...
September 2017: Hematological Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"